报告题目: Cancer Biomarker Discovery via Selective Tissue Proteome Enrichment
报告人: Dr. Cheng S. Lee
University of Maryland, USA
时间: 3月18日(周一) 上午10:00
地点: 卢嘉锡楼报告厅（202）
以下为报告的摘要部分：
Cancer Biomarker Discovery via Selective Tissue Proteome Enrichment
选择性富集的组织蛋白质组学 在癌症生物标记物研究领域的研究和应用
Cheng S. Lee
李春生博士
Department of Chemistry and Biochemistry
化学和生物化学系
University of Maryland
马里兰大学
报告时间：3月18日（周一） 10:00am
报告地点：卢嘉锡楼报告厅（202）
Abstract:
The greatest bioanalytical challenge facing comprehensive proteomic analysis, particularly in the identification of low abundance proteins, is related to the large variation of protein relative abundances. One obvious approach to increase the detection capability of low abundant proteins is to significantly raise the sample loading along with additional fractionation/separation procedures, and therefore is impractical for proteomic studies of small populations of tumor cells microdissected from limited tissue samples. Since the sizes of human tissue biopsies are becoming significantly smaller due to the advent of minimally-invasive methods and early detection and treatment of lesions, our research efforts therefore aim to develop a more effective discovery-based proteomic technology to enable comparative and sensitive studies of protein profiles that will have diagnostic and therapeutic relevance.
Results of oncoproteomic studies of paired primary and recurrent (post-chemotherapy) ovarian high grade serous carcinomas from nine ovarian cancer patients will be presented. Low abundance proteins, such as IL-6 and STAT3 as well as many other proteins known to participate in the IL-6 signaling pathway, are identified and compared for their expression levels within primary and recurrent ovarian carcinomas. For example, RELA and STAT5B are identified as the major over-expressed and carboplatin-resistant proteins in recurrent ovarian carcinoma. Based on shRNA screening for the upregulated genes in in vitro carboplatin-resistant cells, simultaneous knockdown of RELA and STAT5B is most effective in sensitizing tumor cells for carboplatin treatment. Similarly, the use of small molecule inhibitors for RELA and STAT5B significantly enhances cell sensitivity to carboplatin and benefits patients with carboplatin-resistant recurrent ovarian carcinoma.
欢迎感兴趣的老师与学生参加，谢谢 ！
固体表面物理化学国家重点实验室
biwn必赢
2013-03-14
